Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
1don MSN
CEO Albert Bourla says Pfizer has met the strategic goals it had set for itself in 2024, and that it was ‘executing ...
Pfizer’s chief executive said he was “disappointed” with Robert F Kennedy Jr’s refusal to disavow the debunked link between vaccines and autism, even as he expressed confidence that the Trump ...
Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...
With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as ...
Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...
In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...
The pharma executive is optimistic about the new US administration but is also realistic about the risks that come with "radical change." ...
The CEO said last month that the drugmaker had cut costs, revamped its sales operation, and made other big fixes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback